Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s)

J. J. Mule, M. Rosenstein, S. Shu, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

We have studied the in vivo effects of carrageenan and trypan blue on the adoptive immunotherapy of an established local and disseminated syngeneic mouse FBL-3 lymphoma. Mice receiving 500 rads total-body irradiation before injection of FBL-3 tumor into the footpad were treated 4 to 5 days later when a palpable local tumor and disseminated metastases were present. Injection of in vivo immune lymphocytes. I.v. caused complete regression of footpad tumor and cured 96% of all mice (>60 days mean survival; p <0.0005). Carrageenan or trypan blue treatment of the tumor-bearing host abrogated the therapeutic effect of adoptively transferred cells. Cure rates were significantly reduced to 27% (p <0.004) and 0% (p <0.0001) and mean survival times to 40.2 days (p <0.0005) and 15.2 (p <0.005) days for mice treated with carrageenan and trypan blue, respectively, in addition to immune cells. In vivo treatment of the immune spleen cell donors with carrageenan or trypan blue had no significant effect on the ability of those splenocytes to mediate cure when adoptively transferred into tumor-bearing hosts, indicating that the inhibitory activity of these agents cannot be attributed to direct toxicity to immune lymphoid cells. These results demonstrate that a recipient component(s), possibly macrophages, sensitive to carrageenan and to trypan blue but relatively resistant to radiation (500 rads), plays a vital role in the cure of tumor-bearing mice that receive the adoptive transfer of immune splenocytes.

Original languageEnglish (US)
Pages (from-to)526-531
Number of pages6
JournalCancer Research
Volume45
Issue number2
StatePublished - 1985
Externally publishedYes

Fingerprint

Adoptive Transfer
Trypan Blue
Carrageenan
Lymphoma
Lymphocytes
Neoplasms
Adoptive Immunotherapy
Injections
Whole-Body Irradiation
Therapeutic Uses
Spleen
Macrophages
Radiation
Neoplasm Metastasis
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s). / Mule, J. J.; Rosenstein, M.; Shu, S.; Rosenberg, S. A.

In: Cancer Research, Vol. 45, No. 2, 1985, p. 526-531.

Research output: Contribution to journalArticle

@article{74c75cd743354a019591da4134d60796,
title = "Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s)",
abstract = "We have studied the in vivo effects of carrageenan and trypan blue on the adoptive immunotherapy of an established local and disseminated syngeneic mouse FBL-3 lymphoma. Mice receiving 500 rads total-body irradiation before injection of FBL-3 tumor into the footpad were treated 4 to 5 days later when a palpable local tumor and disseminated metastases were present. Injection of in vivo immune lymphocytes. I.v. caused complete regression of footpad tumor and cured 96{\%} of all mice (>60 days mean survival; p <0.0005). Carrageenan or trypan blue treatment of the tumor-bearing host abrogated the therapeutic effect of adoptively transferred cells. Cure rates were significantly reduced to 27{\%} (p <0.004) and 0{\%} (p <0.0001) and mean survival times to 40.2 days (p <0.0005) and 15.2 (p <0.005) days for mice treated with carrageenan and trypan blue, respectively, in addition to immune cells. In vivo treatment of the immune spleen cell donors with carrageenan or trypan blue had no significant effect on the ability of those splenocytes to mediate cure when adoptively transferred into tumor-bearing hosts, indicating that the inhibitory activity of these agents cannot be attributed to direct toxicity to immune lymphoid cells. These results demonstrate that a recipient component(s), possibly macrophages, sensitive to carrageenan and to trypan blue but relatively resistant to radiation (500 rads), plays a vital role in the cure of tumor-bearing mice that receive the adoptive transfer of immune splenocytes.",
author = "Mule, {J. J.} and M. Rosenstein and S. Shu and Rosenberg, {S. A.}",
year = "1985",
language = "English (US)",
volume = "45",
pages = "526--531",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s)

AU - Mule, J. J.

AU - Rosenstein, M.

AU - Shu, S.

AU - Rosenberg, S. A.

PY - 1985

Y1 - 1985

N2 - We have studied the in vivo effects of carrageenan and trypan blue on the adoptive immunotherapy of an established local and disseminated syngeneic mouse FBL-3 lymphoma. Mice receiving 500 rads total-body irradiation before injection of FBL-3 tumor into the footpad were treated 4 to 5 days later when a palpable local tumor and disseminated metastases were present. Injection of in vivo immune lymphocytes. I.v. caused complete regression of footpad tumor and cured 96% of all mice (>60 days mean survival; p <0.0005). Carrageenan or trypan blue treatment of the tumor-bearing host abrogated the therapeutic effect of adoptively transferred cells. Cure rates were significantly reduced to 27% (p <0.004) and 0% (p <0.0001) and mean survival times to 40.2 days (p <0.0005) and 15.2 (p <0.005) days for mice treated with carrageenan and trypan blue, respectively, in addition to immune cells. In vivo treatment of the immune spleen cell donors with carrageenan or trypan blue had no significant effect on the ability of those splenocytes to mediate cure when adoptively transferred into tumor-bearing hosts, indicating that the inhibitory activity of these agents cannot be attributed to direct toxicity to immune lymphoid cells. These results demonstrate that a recipient component(s), possibly macrophages, sensitive to carrageenan and to trypan blue but relatively resistant to radiation (500 rads), plays a vital role in the cure of tumor-bearing mice that receive the adoptive transfer of immune splenocytes.

AB - We have studied the in vivo effects of carrageenan and trypan blue on the adoptive immunotherapy of an established local and disseminated syngeneic mouse FBL-3 lymphoma. Mice receiving 500 rads total-body irradiation before injection of FBL-3 tumor into the footpad were treated 4 to 5 days later when a palpable local tumor and disseminated metastases were present. Injection of in vivo immune lymphocytes. I.v. caused complete regression of footpad tumor and cured 96% of all mice (>60 days mean survival; p <0.0005). Carrageenan or trypan blue treatment of the tumor-bearing host abrogated the therapeutic effect of adoptively transferred cells. Cure rates were significantly reduced to 27% (p <0.004) and 0% (p <0.0001) and mean survival times to 40.2 days (p <0.0005) and 15.2 (p <0.005) days for mice treated with carrageenan and trypan blue, respectively, in addition to immune cells. In vivo treatment of the immune spleen cell donors with carrageenan or trypan blue had no significant effect on the ability of those splenocytes to mediate cure when adoptively transferred into tumor-bearing hosts, indicating that the inhibitory activity of these agents cannot be attributed to direct toxicity to immune lymphoid cells. These results demonstrate that a recipient component(s), possibly macrophages, sensitive to carrageenan and to trypan blue but relatively resistant to radiation (500 rads), plays a vital role in the cure of tumor-bearing mice that receive the adoptive transfer of immune splenocytes.

UR - http://www.scopus.com/inward/record.url?scp=0021911231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021911231&partnerID=8YFLogxK

M3 - Article

C2 - 3881168

AN - SCOPUS:0021911231

VL - 45

SP - 526

EP - 531

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 2

ER -